The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10115 malaria professionals are enjoying the free benefits of MalariaWorld today

Drug Resistance

Molecular detection of drug resistant malaria in Southern Thailand

August 19, 2019 - 17:40 -- Open Access
Author(s): 
Chaturong Noisang, Christiane Prosser, Wieland Meyer, Waenurama Chemoh, John Ellis, Nongyao Sawangjaroen and Rogan Lee
Reference: 
Malaria Journal 2019 18:275, 15 August 2019

Drug resistance within the major malaria parasites Plasmodium vivax and Plasmodium falciparum threatens malaria control and elimination in Southeast Asia. Plasmodium vivax first-line treatment drug is chloroquine together with primaquine, and the first-line treatment for P. falciparum malaria is artemisinin in combination with a partner drug. Plasmodium vivax and P. falciparum parasites resistant to their respective first-line therapies are now found within Southeast Asia. The resistance perimeters may include high transmission regions of Southern Thailand which are underrepresented in surveillance efforts.

Country: 
Medical Condition: 

Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study

January 15, 2019 - 15:19 -- Open Access
Tags: 
Author(s): 
Sachiko Ozawa, Daniel R. Evans, Colleen R. Higgins, Sarah K. Laing and Phyllis Awor
Reference: 
Malaria Journal 2019 18:5, 9 January 2019

Improving the quality of treatment is essential to combat the burden of malaria and prevent the development of drug resistance.

Medical Condition: 
Medical Treatment: 

Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow

July 11, 2017 - 12:53 -- Open Access
Author(s): 
Myo Win Htun, Nan Cho Nwe Mon, Kamala Thriemer, et al.
Reference: 
Malaria Journal 2017 16:281, 10 July 2017

Treatment failures after chloroquine were observed following chloroquine monotherapy, with pvmdr1 amplification present in both Myawaddy and Shwegyin.

Country: 
Medical Condition: 

Genome-wide scans for the identification of Plasmodium vivax genes under positive selection

June 13, 2017 - 16:41 -- Open Access
Author(s): 
Hai-Mo Shen, Shen-Bo Chen, Yue Wang, Bin Xu, Eniola Michael Abe and Jun-Hu Chen
Reference: 
Malaria Journal 2017 16:238, 6 June 2017

This study suggests that greater genetic diversity in P. vivax from CMB area and positive selection signals in invasion and drug resistance genes are consistent with the history of drug use during malaria elimination programme in CMB area.

Medical Condition: 

Metabolic QTL Analysis Links Chloroquine Resistance in Plasmodium falciparum to Impaired Hemoglobin Catabolism

January 7, 2014 - 09:35 -- Open Access
Author(s): 
Ian A. Lewis, Mark Wacker, Kellen L. Olszewski, Simon A. Cobbold, Katelynn S. Baska, Asako Tan, Michael T. Ferdig, Manuel Llinás
Reference: 
PLoS Genet 10(1): e1004085

Drug resistant strains of the malaria parasite, Plasmodium falciparum, have rendered chloroquine ineffective throughout much of the world.

Medical Condition: 
Medical Treatment: 

NOT Open Access | From a cytotoxic agent to the discovery of a novel antimalarial agent

January 4, 2013 - 07:08 -- NOT Open Access
Author(s): 
Ravi S.P. Singh, Umashankar Das, Jennifer M. Auschwitz, Susan E. Leed, Mark R. Hickman, Jonathan R. Dimmock, Jane Alcorn
Reference: 
Bioorganic & Medicinal Chemistry Letters, Volume 23, Issue 2, 15 January 2013, Pages 584–587
MalariaWorld

A novel cytotoxin 3,5-bis(4-chlorobenzylidene)-1-[4-{2-(4-morpholinyl)ethoxy}phenyl-carbonyl]-4-piperidone hydrochloride 2 demonstrated potent antimalarial properties with IC50 values of 0.60 and 1.97 μM against the drug sensitive D6 strain and the C235 drug-resistant strain of Plasmodium falciparum.

Medical Condition: 

Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite

August 8, 2012 - 07:20 -- Kabogo Ndegwa
Author(s): 
Daniel J. Park, Amanda K. Lukens, Sarah K. Volkman, et al.
Reference: 
PNAS August 7, 2012 vol. 109 no. 32 13052-13057

MalariaWorldThrough rapid genetic adaptation and natural selection, the Plasmodium falciparum parasite—the deadliest of those that cause malaria—is able to develop resistance to antimalarial drugs, thwarting present efforts to control it.

Functional Characterization of the Plasmodium falciparum Chloroquine-Resistance Transporter (PfCRT) in Transformed Dictyostelium discoideum Vesicles

June 26, 2012 - 11:22 -- Kabogo Ndegwa
Author(s): 
Janni Papakrivos, Juliana M. Sá, Thomas E. Wellems
Reference: 
PLoS ONE 7(6): e39569

MalariaWorldIsolated vesicles from mutant-PfCRT-transformed D. discoideum exhibit features of the CQR phenotype, consistent with evidence that the drug resistance mechanism operates at the P. falciparum digestive vacuole membrane in malaria.

Medical Treatment: 

Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal

June 20, 2012 - 08:59 -- Kabogo Ndegwa
Author(s): 
Wurtz N, Fall B, Pascual A, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Diémé Y, Rogier C, Bercion R, Briolant S, Wade B, Pradines B
Reference: 
Malaria Journal 2012, 11:197 (13 June 2012)

MalariaWorldSince 2004, the prevalence of chloroquine resistance had decreased.

Country: 
City: 
Medical Treatment: 

NOT Open Access | Sontochin as a Guide to the Development of Drugs against Chloroquine-Resistant Malaria

June 19, 2012 - 11:39 -- Kabogo Ndegwa
Author(s): 
Sovitj Pou, Rolf W. Winter, Aaron Nilsen, Jane Xu Kelly, Yuexin Li, J. Stone Doggett, Erin W. Riscoe, Keith W. Wegmann, David J. Hinrichs, and Michael K. Riscoe
Reference: 
Antimicrob. Agents Chemother. July 2012 vol. 56 no. 7 3475-3480

MalariaWorldSontochin was the original chloroquine replacement drug, arising from research by Hans Andersag 2 years after chloroquine (known as “resochin” at the time) had been shelved due to the mistaken perception that it was too toxic for human use.

Pages

Subscribe to RSS - Drug Resistance